Tremelimumab

Therapeutic indications

Tremelimumab is indicated for:

Hepatocellular carcinoma (HCC)

Population group: only adults (18 years old or older)

It is indicated in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tremelimumab is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Corticosteroids (except physiological dose) or immunosuppressants before starting tremelimumab

at least one of
Corticosteroid drugs
Immunosuppressants

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: IMJUDO Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈